公开(公告)号：US10272052B2

公开(公告)日：2019-04-30

申请号：US15905748

申请日：2018-02-26

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K9/00 ,  A61P25/28 ,  A61K31/055

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.

公开(公告)号：US10765755B1

公开(公告)日：2020-09-08

申请号：US14548996

申请日：2014-11-20

Applicant: Umesh Kumar Jinwal ,  Vijaykumar Bhadabhai Sutariya

Inventor： Umesh Kumar Jinwal ,  Vijaykumar Bhadabhai Sutariya

IPC: A61K31/5415 ,  A61K47/48 ,  A61K9/51

Abstract: A delivery system of coated and uncoated nanoparticles (NP) for delivery of methylene blue (MB). The delivery system was developed using PLGA-based polymer that was repeatedly shown to be biocompatible and biodegradable. The parameters of synthesized NPs were within the suitable range for BBB permeation—specifically, the NPs were monodispersed, with slight negative charge, and with the size within 100-150 nm range suitable for intravenous delivery and delivery to the brain. The coating on the nanoparticle did not have a significant impact on the nanoparticle size and zeta potential. Based on the immunoblotting experiments using AD cellular model, the GSH coated NPs were better in reducing tau levels compared to MB solution. In vitro BBB Transwell permeation study showed eight fold higher MB-NP permeation compared to the MB solution over 24 hours.

公开(公告)号：US10758520B1

公开(公告)日：2020-09-01

申请号：US16271018

申请日：2019-02-08

Applicant: Vijaykumar Bhadabhai Sutariya ,  Umesh Kumar Jinwal

Inventor： Vijaykumar Bhadabhai Sutariya ,  Umesh Kumar Jinwal

IPC: A61K31/4439 ,  A61K9/51

Abstract: Nanoparticle based MKT formulation. MKT is encapsulated by poly(ethylene glycol)ylated (PEGylated) poly-(lactide-co-glycolide) (PLGA) to form nanoparticles (NPs). To induce trans-BBB permeability, glutathione (GSH) is coated on the resulting NPs. Newly generated MKT-NPs showed BBB permeability and tau reduction in experimental models. Specifically, brain-targeting MKT NPs were developed with a glutathione coating, characterized, and shown to permeate BBB permeation insert models as a therapeutic for Alzheimer's disease and related tauopathies.

公开(公告)号：US20190298663A1

公开(公告)日：2019-10-03

申请号：US16293535

申请日：2019-03-05

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K31/055 ,  A61P25/28 ,  A61K9/00

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.

公开(公告)号：US20180250241A1

公开(公告)日：2018-09-06

申请号：US15905748

申请日：2018-02-26

Applicant: Umesh Kumar Jinwal ,  Vetriselvan Manavalan

Inventor： Umesh Kumar Jinwal ,  Vetriselvan Manavalan

IPC: A61K31/055 ,  A61K9/00 ,  A61P25/28

CPC classification number: A61K31/055 ,  A61K9/0019 ,  A61P25/28

Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.